Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2005;45:1139-1144
Published online before print April 25, 2005, doi: 10.1161/01.HYP.0000164572.92049.29
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/6/1139    most recent
01.HYP.0000164572.92049.29v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, R.
Right arrow Articles by de Champlain, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, R.
Right arrow Articles by de Champlain, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Remodeling
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Hypertrophy
Right arrow Oxidant stress

(Hypertension. 2005;45:1139.)
© 2005 American Heart Association, Inc.


Original Articles

Cyclooxygenase-2 Inhibitors Attenuate Angiotensin II–Induced Oxidative Stress, Hypertension, and Cardiac Hypertrophy in Rats

Rong Wu; Marc-André Laplante; Jacques de Champlain

From the Department of Physiology, University de Montréal, Montréal, Canada.

Correspondence to Jacques de Champlain, MD, PhD, Department of Physiology, Faculty of Medicine, University of Montreal, CP 6128, Succursale Centreville, Montréal, Québec, Canada, H3C 3J7. E-mail grsna{at}ere.umontreal.ca

Angiotensin II is an important oxidative stress mediator. Our previous studies have indicated that the potent antioxidative properties of acetylsalicylic acid play an important role in its cardiovascular protective effects. There are some ongoing controversies concerning the use of selective cyclooxygenase-2 inhibitors in cardiovascular disease. The aim of this study was to determine whether the cyclooxygenase-2 selective inhibitors rofecoxib and nimesulide possess antioxidative and cardiovascular protective effects against angiotensin II. Chronic subcutaneous angiotensin II infusion increased cardiovascular but not colonic tissue superoxide production, heart/body weight ratio, and blood pressure. Moreover, angiotensin II selectively increased cardiac cyclooxygenase-2 but not cyclooxygenase-1 expression, which was totally prevented by acetylsalicylic acid treatment. Similar to acetylsalicylic acid, rofecoxib or nimesulide treatments significantly attenuated angiotensin II–induced oxidative stress, hypertension, and cardiac NAD(P)H oxidase subunit p47phox expression. Rofecoxib also reduced cardiac hypertrophy. Treatment with nonselective anti-inflammatory drugs ibuprofen, indomethacin, or salicylic acid did not show any effect on angiotensin II–induced superoxide production, hypertension, or cardiac hypertrophy. Although acetylsalicylic acid and salicylic acid inhibited angiotensin II–induced nuclear factor {kappa}B (NF-{kappa}B) activation, nimesulide did not modify NF-{kappa}B activation. In conclusion, cyclooxygenase-2 pathway is implicated in angiotensin II–induced oxidative stress and deleterious cardiovascular changes. Rofecoxib and nimesulide produced significant antioxidative effect by reducing NAD(P)H oxidase–dependent superoxide generation. These effects seem to be independent of NF-{kappa}B inhibition.


Key Words: cyclooxygenase • oxidative stress • angiotensin II • free radicals • hypertension, experimental




This article has been cited by other articles:


Home page
Evid Based Complement Alternat MedHome page
A. Iyer and L. Brown
Fermented Wheat Germ Extract (Avemar) in the Treatment of Cardiac Remodeling and Metabolic Symptoms in Rats
Evid. Based Complement. Altern. Med., July 21, 2009; (2009) nep090v1.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. J. Welch
Angiotensin II-Dependent Superoxide: Effects on Hypertension and Vascular Dysfunction
Hypertension, July 1, 2008; 52(1): 51 - 56.
[Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
X.-J. Zou, L. Yang, and S.-L. Yao
Propofol Depresses Angiotensin II-Induced Cardiomyocyte Hypertrophy In Vitro
Experimental Biology and Medicine, February 1, 2008; 233(2): 200 - 208.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Taurin, K. Hogarth, N. Sandbo, D. M. Yau, and N. O. Dulin
G{beta}{gamma}-mediated Prostacyclin Production and cAMP-dependent Protein Kinase Activation by Endothelin-1 Promotes Vascular Smooth Muscle Cell Hypertrophy through Inhibition of Glycogen Synthase Kinase-3
J. Biol. Chem., July 6, 2007; 282(27): 19518 - 19525.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
T. Vera, S. Kelsen, L. L. Yanes, J. F. Reckelhoff, and D. E. Stec
HO-1 induction lowers blood pressure and superoxide production in the renal medulla of angiotensin II hypertensive mice
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1472 - R1478.
[Abstract] [Full Text] [PDF]